Search the GHTC website

Global health R&D delivers for Pennsylvania

US government investment in global health R&D has delivered

$352.8 million
to Pennsylvania research institutions
4,300+ new jobs
for Pennsylvania
Global health R&D at work in Pennsylvania

Once HIV therapy is working, HIV can lie dormant in immune cells at low levels. It is critical to determine if this latent HIV reservoir, often containing damaged HIV, could create more virus and cause relapse if treatment is stopped. Now researchers at the University of Pittsburgh have created a test to detect this “hidden” HIV. The test is faster, easier on patients, less labor-intensive, less expensive, and more sensitive than the current gold-standard test.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Scott Areman